锐客网

  1. 首页 > 生活杂烩 > 健康 > >

胰腺神经内分泌瘤|徐建明教授点评｜G2级胰腺神经内分泌瘤根治性切除术后长效奥曲肽辅助治疗( 二 )


6
结论
G2 pNET根治性切除术后应用长效奥曲肽辅助治疗3y-DFS获益，但仍需设计严谨的大型随机对照研究对治疗的收益及获益患者类型进行验证 。
参考文献：（向上滑动阅览）
1.Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335‐1342. doi:10.1001/jamaoncol.2017.0589
2.Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8‐e21. doi:10.1016/S1470-2045(13)70362-0
3.Fan JH, Zhang YQ, Shi SS, et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget. 2017;8(42):71699‐71708. Published 2017 May 3. doi:10.18632/oncotarget.17599
4.National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines in Oncology. Neuroendocrine and adrenal tumors, Version 1. 2019.
5.Singh S, Chan DL, Moody L, et al. Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4(4):583‐585. doi:10.1001/jamaoncol.2018.0024
6.Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256(2):321‐325. doi:10.1097/SLA.0b013e31824e6108
7.Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063‐3072. doi:10.1200/JCO.2007.15.4377
8.Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733‐1742. doi:10.1093/annonc/mdl105
9.Jann H, Denecke T, Koch M, Pape UF, Wiedenmann B, Pavel M. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology. 2013;98(2):137‐143. doi:10.1159/000353785
10.Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656‐4663. doi:10.1200/JCO.2009.22.8510
11.Arai T, Kobayashi A, Fujinaga Y, et al. Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection. Pancreatology. 2016;16(3):397‐402. doi:10.1016/j.pan.2016.01.002
12.Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247(3):490‐500. doi:10.1097/SLA.0b013e31815b9cae
13.Tsutsumi K, Ohtsuka T, Fujino M, et al. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. J Hepatobiliary Pancreat Sci. 2014;21(6):418‐425. doi:10.1002/jhbp.47.
14.Han X, Zhang C, Tang M, et al. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. Eur J Gastroenterol Hepatol. 2015;27(5):527‐535. doi:10.1097/MEG.0000000000000332
15.Jin K, Luo G, Xu J, et al. Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. Oncol Lett. 2017;13(5):3163‐3168. doi:10.3892/ol.2017.5834
16.Xu X, Han X, Liu L, Ji Y, Li J, Lou W. Clinical Analysis and Comprehensive Treatment of Nonfunctional Pancreatic Neuroendocrine Tumor With Liver Metastases: A Retrospective Single-Center Study. Pancreas. 2015;44(6):995‐996. doi:10.1097/MPA.0000000000000342

推荐阅读


上一篇：抗生素|两大抗生素：阿莫西林和头孢，其实有区别！用对是宝，用错有害

下一篇：医生|医生喝葡萄糖为什么会引发争议？